Literature DB >> 17509331

Selective, concurrent bilateral nephrectomies at renal transplantation for autosomal dominant polycystic kidney disease.

Matthew D Wagner1, Jonathan C Prather, John M Barry.   

Abstract

PURPOSE: An algorithm was developed for performing bilateral nephrectomies for specific indications before or at renal transplantation in patients with autosomal dominant polycystic kidney disease. Outcomes for the living donor arm of the algorithm are reported.
MATERIALS AND METHODS: Patients with autosomal dominant polycystic kidney disease and end stage renal disease were evaluated for transplantation. Patients with recurrent pyelonephritis, hemorrhage, pain, early satiety or kidneys that extended into the true pelvis underwent bilateral nephrectomies. Bilateral nephrectomies with concurrent renal transplantation were performed if a living renal donor was identified. If no living donor was identified, pre-transplantation bilateral nephrectomies were done and the patients were listed for cadaveric donor renal transplantation. The living renal donor arm of the algorithm was evaluated by comparing certain parameters for 15 and 17 patients with autosomal dominant polycystic kidney disease who underwent pre-transplantation and concurrent bilateral nephrectomies, respectively, including patient and graft survival, delayed graft function, graft function, length of stay for each surgery, transfusions and complications.
RESULTS: No deaths, graft failures or delayed graft function occurred. In the delayed renal transplant group median time from nephrectomy to living donor transplantation was 124 days. Serum creatinine at discharge home and 1 year after transplantation for the pre-transplantation nephrectomy cohort was 2.0 and 1.3 mg/dl, respectively. Seven of the 17 patients with concurrent nephrectomy underwent transplantation before starting renal replacement therapy. A longer mean total hospital stay in the pre-transplantation nephrectomy cohort was the only statistically significance outcome variable.
CONCLUSIONS: Selective bilateral nephrectomies at living donor renal transplantation results in decreased total length of stay without compromising patient or graft outcomes and it allows preemptive renal transplantation. Concurrent nephrectomy is safe and it further validates the algorithm for selective, concurrent bilateral nephrectomies for patients with autosomal dominant polycystic kidney disease who undergo living donor renal transplantation.

Entities:  

Mesh:

Year:  2007        PMID: 17509331     DOI: 10.1016/j.juro.2007.01.146

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Laparoscopic pretransplant nephrectomy with morcellation in autosomic-dominant polycystic kidney disease patients with end-stage renal disease.

Authors:  Anastasios D Asimakopoulos; Richard Gaston; Roberto Miano; Filippo Annino; Camille Mugnier; Lorenzo Dutto; Giuseppe Vespasiani; Enrico Spera; Jean-Luc Hoepffner; Thierry Piechaud
Journal:  Surg Endosc       Date:  2014-08-15       Impact factor: 4.584

2.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda J Page; Vickie J Kubly; Eric J Bergstralh; Xujian Li; Bohyun Kim; Bernard F King; James Glockner; David R Holmes; Sandro Rossetti; Peter C Harris; Nicholas F LaRusso; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 10.121

Review 3.  Tailoring the 'Perfect Fit' for Renal Transplant Recipients with End-stage Polycystic Kidney Disease: Indications and Timing of Native Nephrectomy.

Authors:  Chrysoula Argyrou; Demetrios Moris; Spyridon Vernadakis
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 4.  Renal transplantation in autosomal dominant polycystic kidney disease.

Authors:  Nada Kanaan; Olivier Devuyst; Yves Pirson
Journal:  Nat Rev Nephrol       Date:  2014-06-17       Impact factor: 28.314

5.  Maximal kidney length predicts need for native nephrectomy in ADPKD patients undergoing renal transplantation.

Authors:  Octav Cristea; Daniel Yanko; Sarah Felbel; Andrew House; Alp Sener; Patrick P W Luke
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

6.  Live Donor Renal Transplant With Simultaneous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease Is Feasible and Satisfactory at Long-term Follow-up.

Authors:  Sarwat B Ahmad; Brian Inouye; Michael S Phelan; Andrew C Kramer; Jay Sulek; Matthew R Weir; Rolf N Barth; John C LaMattina; Eugene J Schweitzer; David B Leeser; Silke V Niederhaus; Stephen T Bartlett; Jonathan S Bromberg
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939

7.  Native Nephrectomy in Renal Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Fouad T Chebib; Mikel Prieto; Yeonsoon Jung; Maria V Irazabal; Walter K Kremers; Patrick G Dean; David J Rea; Fernando G Cosio; Vicente E Torres; Ziad M El-Zoghby
Journal:  Transplant Direct       Date:  2015-11-18

8.  Simultaneous ipsilateral nephrectomy during kidney transplantation in autosomal dominant polycystic kidney disease: a matched pair analysis of 193 consecutive cases.

Authors:  Bernd Martin Jänigen; Johann Hempel; Philipp Holzner; Johanna Schneider; Stefan Fichtner-Feigl; Oliver Thomusch; Hannes Neeff; Przemyslaw Pisarski; Torben Glatz
Journal:  Langenbecks Arch Surg       Date:  2020-07-23       Impact factor: 3.445

9.  Concomitant laparoscopic urological procedures: Does it contribute to morbidity?

Authors:  Kamlesh Maurya; S E Sivanandam; Sudhir Sukumar; Sanjay Bhat; Ginil Kumar; Balagopal Nair
Journal:  J Minim Access Surg       Date:  2009 Jul-Sep       Impact factor: 1.407

10.  Trends in the management and outcomes of kidney transplantation for autosomal dominant polycystic kidney disease.

Authors:  Madhukar S Patel; Praveen Kandula; David Wojciechowski; James F Markmann; Parsia A Vagefi
Journal:  J Transplant       Date:  2014-08-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.